Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4161/cbt.29928 http://scihub22266oqcxt.onion/10.4161/cbt.29928 C4130722!4130722 !25046606     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25046606 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 243.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25046606 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cancer+Biol+Ther 2014 ; 15 (10 ): 1299-300 Nephropedia Template TP {{tp|p=25046606 |t=2014. Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer |pdf=|usr=}}{{25046606 }} gab.com Text Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer JO: Cancer Biol Ther http://www.kidney.de/pget.php?&tw=1&pmid=25046606 #FOAvip Immunotherapy has garnered an important place in the therapeutic landscape of treatment in prostate cancer since approval of sipuleucel-T. Ipilimumab is a checkpoint inhibitor that is currently approved for the treatment of advanced melanoma. In the June issue of Lancet Oncology, Kwon and colleagues report the phase III trial using ipilimumab in a post-docetaxel metastatic castration-resistant prostate cancer population. While the primary endpoint of overall survival was not met, several lessons are learned from the analysis of this trial. Perhaps better refinement of a more favorable group of patients who may potentially benefit from an immunologic treatment should be advocated. Twit Text FOAVip Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer ????Cancer Biol Ther http://www.kidney.de/pget.php?&tw=1&pmid=25046606 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25046606 #FOAvip English Wikipedia <ref>{{Cite pmid|25046606 }}</ref> Ipilimumab: a potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer #MMPMID25046606 Kittai A ; Meshikhes M ; Aragon-Ching JB Cancer Biol Ther 2014[Oct]; 15 (10 ): 1299-300 PMID25046606 show ga Immunotherapy has garnered an important place in the therapeutic landscape of treatment in prostate cancer since approval of sipuleucel-T. Ipilimumab is a checkpoint inhibitor that is currently approved for the treatment of advanced melanoma. In the June issue of Lancet Oncology, Kwon and colleagues report the phase III trial using ipilimumab in a post-docetaxel metastatic castration-resistant prostate cancer population. While the primary endpoint of overall survival was not met, several lessons are learned from the analysis of this trial. Perhaps better refinement of a more favorable group of patients who may potentially benefit from an immunologic treatment should be advocated. |*Immunotherapy [MESH] |Cancer Vaccines/*therapeutic use [MESH] |Humans [MESH] |Intercellular Adhesion Molecule-1/*therapeutic use [MESH] |Male [MESH] |Prostatic Neoplasms/*therapy [MESH]Ipilimumab: a potential immunologic agent in the treatment of metastat(epmc).pdf DeepDyve Pubget Overpricing